中国科学院 微生物研究所中国科学院 微生物研究所

研究成果

論文発表　 学会発表　

論文発表

2024

  1. Adachi T, Nakamura S, Michishita A, Kawahara D, Yamamoto M, Hamada M, Nakamura Y. RaptGen-assisted generation of an RNA/DNA hybrid aptamer against SARS-CoV-2 spike psrotein. Biochemistry. doi: 10.1021/acs.biochem.3c00596. Epub ahead of print. PMID: 38457656. (MAR 2024)

2023

  1. Hassan AHE, El-Sayed SM, Yamamoto M, Gohda J, Matsumoto T, Shirouzu M, Inoue J-i, Kawaguchi Y, Mansour RMA, Anvari A, Farahat AA. In Silico and In vitro evaluation of some amidine derivatives as hit compounds towards development of inhibitors against coronavirus diseases. Viruses 15(5): 1171, 2023. doi: 10.3390/v15051171. (MAY 2023)
  2. Hayashi Y, Nakayama J, Yamamoto M, Maekawa M, Watanabe S, Higashiyama S, Inoue JI, Yamamoto Y, Semba K. Aberrant accumulation of NIK promotes tumor growth by dysregulating translation and post-translational modifications in breast cancer. Cancer Cell Int 23(1): 57, 2023. doi: 10.1186/s12935-023-02904-y. (APR 2023)
  3. Hayashi Y, Huang X, Tanikawa T, Tanigawa K, Yamamoto M, Gohda J, Inoue JI, Fukase K, Kabayama K. Reactive oxygen species are associated with the inhibitory effect of N-(4-hydroxyphenyl)-retinamide on the entry of the severe acute respiratory syndrome-coronavirus 2. J Biochem: mvad020. doi: 10.1093/jb/mvad020. Epub ahead of print. PMID: 36888972. (MAR 2023)

2022

  1. Ogura H, Gohda J, Lu X, Yamamoto M, Takesue Y, Son A, Doi S, Matsushita K, Isobe F, Fukuda Y, Huang TP, Ueno T, Mambo N, Murakami H, Kawaguchi Y, Inoue JI, Shirai K, Yamasaki S, Hirata JI, Ishido S. Dysfunctional Sars-CoV-2-M protein-specific cytotoxic T lymphocytes in patients recovering from severe COVID-19. Nat Commun 13(1): 7063. (DEC 2022)
  2. Yamamoto M, Gohda J, Kobayashi A, Tomita K, Hirayama Y, Koshikawa N, Seiki M, Semba K, Akiyama T, Kawaguchi Y, Inoue JI. Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein. mBio e0051922, 2022. doi: 10.1128/mbio.00519-22. (JUN 2022)
  3. Yamamoto M, Tomita K, Hirayama Y, Inoue JI, Kawaguchi Y, Gohda J. SARS-CoV-2 Omicron spike H655Y mutation is responsible for enhancement of the endosomal entry pathway and reduction of cell surface entry pathways. BioRxiv, 2022. doi: https://doi.org/10.1101/2022.03.21.485084 (MAR 2022)

2021

  1. Kawashima K, Hirota-Tsukimachi M, Toma T, Koga R, Iwamaru K, Yanae M, Ahagon A, Nakamura Y, Anraku K, Tateishi H, Gohda J, Inoue JI, Otsuka M, Fujita M. Development of chimeric receptor activator of nuclear factor-kappa B with glutathione S-transferase in the extracellular domain: Artificial switch in a membrane receptor. Chem Biol Drug Des 99(4): 573-584, 2021. (DEC 2021)
  2. Yamamoto M, Gohda J, Cell-based membrane fusion assays with viral fusion proteins for identification of entry inhibitors. Translational and Regulatory Sciences 3(3): 72-76. (DEC 2021)
  3. Takeuchi Y, Kimura N, Murayama T, Machida Y, Iejima D, Nishimura T, Terashima M, Wang Y, Li M, Sakamoto R, Yamamoto M, Itano N, Inoue Y, Ito M, Yoshida N, Inoue JI, Akashi K, Saya H, Fujita K, Kuroda M, Kitabayashi I, Voon D, Suzuki T, Tojo A, Gotoh N. The membrane-linked adaptor FRS2β fashions a cytokine-rich inflammatory microenvironment that promotes breast cancer carcinogenesis. Proc Natl Acad Sci USA 118(43): e2103658118. doi: 10.1073/pnas.2103658118. (OCT 2021)
  4. Deletsu SD, Kitamura H, Ishida T, Gohda J, Yamaoka S, Takeuchi H. Identification and characterization of Stathmin 1 as a host factor involved in HIV-1 latency. Biochem Biophys Res Commun 567: 106-111, 2021 (AUG 2021)
  5. Hayashi Y, Tsuchiya K, Yamamoto M, Nemoto-Sasaki Y, Tanigawa K, Hama K, Ueda Y, Tanikawa T, Gohda J, Maeda K, Inoue J, Yamashit A. N-(4-Hydroxyphenyl) retinamide suppresses SARS-CoV-2 spike protein-mediated cell-cell fusion by a dihydroceramide Δ4-desaturase 1-independent mechanism. Journal of Virology 10;95(17), 2021 (AUG 2021)
  6. Kandeel M, Yamamoto M, Park BK, Al-Taher A, Watanabe A, Gohda J, Kawaguchi Y, Oh-hashi K, Kwon HJ, Inoue JI. Discovery of new potent anti-MERS CoV fusion inhibitors. Frontiers in Pharmacology 12: 685161, 2021. (JUN 2021)
  7. Kandeel M, Yamamoto M, Tani H, Kobayashi A, Gohda J, Kawaguchi Y, Park BK, Kwon HJ, Inoue JI, Alkattan A. Discovery of new fusion inhibitor peptides against SARS-CoV-2 by targeting the spike S2 subunit. Biomolecules & Therapeutics 29(3): 282-289. (MAY 2021)
  8. Yamamoto M, Gohda J, Akiyama T, Inoue JI. TNF receptor-associated factor 6 (TRAF6) plays crucial roles in multiple biological systems through polyubiquitination-mediated NF-κB activation. Proc Jpn Acad Ser B Phys Biol Sci 97(4): 145-160. (APR 2021)

2020

  1. Yamamoto M, Ichinohe T, Watanabe A, Kobayashi A, Zhang R, Song J, Kawaguchi Y, Matsuda Z, Inoue JI. The Antimalarial compound atovaquone inhibits Zika and Dengue virus infection by blocking E protein-mediated membrane fusion. Viruses 12 (12), 1475, 2020. (DEC 2020)
  2. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Viruses 12(6): 629, 2020. (JUN 2020)
  3. Yamamoto M, Kiso M, Sakai-Tagawa Y, Iwatsuki-Horimoto K, Imai M, Takeda M, Kinoshita N, Ohmagari N, Gohda J, Semba K, Matsuda Z, Kawaguchi Y, Kawaoka Y, Inoue JI. The anticoagulant nafamostat potently inhibits SARS-CoV-2 infection in vitro: an existing drug with multiple possible therapeutic effects. BioRxiv doi: https://doi.org/10.1101/2020.04.22.054981, 2020. (APR 2020)
    https://www.biorxiv.org/content/10.1101/2020.04.22.054981v1
  4. Nakamura T, Hashikawa C, Okabe K, Yokote Y, Chirifu M, Toma-Fukai S, Nakamura N, Matsuo M, Kamikariya M, Okamoto Y, Gohda J, Akiyama T, Semba K, Ikemizu S, Ostuka M, Inoue JI, Yamagata Y. Structural analysis of TIFA: Insight into TIFA-dependent signal transduction in innate Immunity. Sci Rep 10(1): 5152, 2020. (MAR 2020)
  5. Kandeel M, Yamamoto M, Al-Taher A, Watanabe A, Oh-Hashi K, Park BK, Kwon HJ, Inoue JI, Al-Nazawi M. Small molecule inhibitors of middle east respiratory syndrome coronavirus fusion by targeting cavities on heptad repeat trimers. Biomol Ther (Seoul) doi:10.4062/biomolther.2019.202., 2020. (MAR 2020)

2018

  1. Gohda J, Suzuki K, Liu K, Xie X, Takeuchi H, Inoue J, Kawaguchi Y, Ishida T. BI-2536 and BI-6727, dual Polo-like kinase/bromodomain inhibitors, effectively reactivate latentHIV-1. Scientific Reports 8 (1): 3521. doi: 10.1038/s41598-018-21942-5, 2018. (FEB 2018)

2015

  1. Liu C, Zhao Y, He W, Wang W, Chen Y, Zhang S, Ma Y, Gohda J, Ishida T, Walter TS, Owens RJ, Stuart DI, Ren J, Gao B. A RANKL mutant used as an inter-species vaccine for efficient immunotherapy of osteoporosis. Sci Rep 5:14150, 2015. (SEP 28, 2015）
  2. Gu L, Han Y, Li Y, Zhu T, Song X, Huang H, Yang F, Guan S, Xie J, Gohda J, Hosoya N, Kawana-Tachikawa A, Liu W, Gao GF, Iwamoto A, Li T, Ishida T. Emergence of Lamivudine-Resistant HBV during Antiretroviral Therapy Including Lamivudine for Patients Coinfected with HIV and HBV in China. PLoS ONE 10(8):e0134539, 2015. (AUG 2015)
  3. Li Y, Gu L, Han Y, Xie J, Wang H, Lv W, Song X, Li Y, Iwamoto A, Ishida T, Li T. HIV-1 subtype B/B' and baseline drug resistance mutation are associated with virologic failure: a multicenter cohort study in China. J Acquir Immune Defic Syndr 68(3):289-97, 2015. (MAR 2015)
  4. Gohda J, Ma Y, Huang Y, Zhang Y, Gu L, Han Y, Li T, Gao B, Gao GF, Inoue J-i, Iwamoto A, Ishida T. HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro. Retrovirology 12:12, 2015. (FEB 7, 2015)
  5. Matsuda Y, Kobayashi-Ishihara M, Fujikawa D, Ishida T, Watanabe T, Yamagishi M. Epigenetic heterogeneity in HIV-1 latency establishment. Sci Rep 5:7701, 2015.（JAN 9, 2015）
  6. Nakayama-Hosoya K, Ishida T, Youngblood B, Nakamura H, Hosoya N, Koga M, Koibuchi T, Iwamoto A, Kawana-Tachikawa A. Epigenetic repression of interleukin 2 expression in senescent CD4+ T cells during chronic HIV type 1 infection. J Infect Dis 211:28-39, 2015. (JAN 1, 2015)

2014

  1. Gu L, Kawana-Tachikawa A, Shiino T, Nakamura H, Koga M, Kikuchi T, Adach E, Koibuchi T, Ishida T, Gao GF, Matsushita M, Sugiura W, Iwamoto A, Hosoya N. Development and Customization of a Color-Coded Microbeads-Based Assay for Drug Resistance in HIV-1 Reverse Transcriptase. PLos ONE 9: e09823, OCT 2014.
  2. Li Y, Han Y, Xie J, Gu L, Li W, Wang H, Li W, Song X, Li Y, Routy JP, Ishida T, Iwamoto A and Li T. CRF01_AE subtype is associated with X4 tropism and fast HIV progression in Chinese patients infected through sexual transmission. AIDS, 28, 521-530, FEB 20 2014

2013

  1. Suzuki K, Hattori S, Marks K, Ahlenstiel C, Maeda Y, Ishida T, Millington M, Boyd M, Symonds G, Cooper DA, Okada S, Kelleher AD. Promoter targeting shRNA suppresses HIV-1 infection in vivo through transcriptional gene silencing. Mol Ther Nucleic Acids. 2013 Dec 3;2:e137.
  2. Ohsugi T, Ishida T, Shimasaki T, Okada S, Umezawa K. p53 dysfunction precedes the activation of nuclear factor-κB during disease progression in mice expressing Tax, a human T-cell leukemia virus type 1 oncoprotein. Carcinogenesis, 34(9), 2129-36, 2013 Sep
  3. Nakano K, Ando T, Yamagishi M, Yokoyama K, Ishida T, Ohsugi T, Tanaka Y, Brighty DW, Watanabe T. Viral interference with host mRNA surveillance, the nonsense-mediated mRNA decay (NMD) pathway, through a new function of HTLV-1 Rex: implications for retroviral replication. Microbes Infect, 15, 491-505, JUN 2013.

2012

  1. Saito M, Kato Y, Ito E, Fujimoto J, Ishikawa K, Doi A, Kumazawa K, Matsui A, Takebe S, Ishida T, Azuma S, Mochizuki H, Kawamura Y, Yanagisawa Y, Honma R, Imai J, Ohbayashi H, Goshima N, Semba K, Watanabe S. Expression screening of 17q12-21 amplicon reveals GRB7 as an ERBB2-dependent oncogene. FEBS Lett. 12;586(12):1708-14, 2012.
  2. Kobayashi-Ishihara M, Yamagishi M, Hara T, Matsuda Y, Takahashi R, Miyake A, Nakano K, Yamochi T, Ishida T, Watanabe T. HIV-1-encoded antisense RNA suppresses viral replication for a prolonged period. Retrovirology.9:38, 2012. （doi:10.1186/1742-4690-9-38.）
  3. Taguchi, Y., Kiga, Y., Gohda, J.Inoue, J-I. Identification and characterization of anti-osteoclastogenic peptides derived from the cytoplasmic tail of RANK. J. Bone Miner. Metab. in press, 2012.（DOI: 10.1007/s00774-012-0353-5）
  4. Ahlenstiel C, Lim H, Cooper DA, Ishida T, Kelleher, AD, Suzuki, K. Direct evidence of nuclear Argonaute distribution during transcriptional silencing links the actin cytoskeleton to nuclear RNAi machinery in human cells. Nucleic Acids Research. 40:1579-1595, 2012.

2011

  1. Suzuki K, Ishida T, Yamagishi M, Ahlenstiel C, Swaminathan S, Marks K, Murray D, McCartney EM, Beard MR, Alexander M, Purcell DF, Cooper DA, Watanabe T, Kelleher AD. Transcriptional gene silencing of HIV-1 through promoter targeted RNA is highly specific. RNA Biology. 8:1035-46, 2011.
  2. Tsai HJ, Kobayashi S, Izawa K, Ishida T, Watanabe T, Umezawa K, Lin SF, Tojo A. Bioimaging analysis of nuclear factor-κB activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer Sci. 102(11):2014-21, 2011.
  3. Shi G, Yagyu F, Shimizu Y, Shimizu K, Oshima M, Iwamoto A, Gao B, Liu W, Gao GF, Kitamura Y. Flow cytometric assay using two fluorescent proteins for the function of the internal ribosome entry site of hepatitis C virus. Cytometry: Part A. 79A: 653-660,2011.

2010

  1. Sun Y, Liu J, Yang M, Gao F, Zhou J, Kitamura Y, Gao B, Tien P, Shu Y, Iwamoto A, Chen Z, Gao GF. Identification and structural definition of H5-specific CTL epitopes restricted by HLA-A*0201 derived from the H5N1 subtype of influenza A viruses. J Gen Virol. 91:919-30, 2010.
  2. Song XH, Xiao H, Huang Y, Fu G, Jiang B, Kitamura Y, Liu W, Liu D, Gao GF. Serological surveillance of influenza A virus infection in swine populations in Fujian province, China: no evidence of naturally occurring H5N1 infection in pigs. Zoonoses Public Health. 57:291-8, 2010.
  3. Yu M, Liu X, Sun L, Chen C, Ma G, Kitamura Y, Gao GF, Liu W. Subcellular localization and topology of porcine reproductive and respiratory syndrome virus E protein. Virus Res. 152:104-14, 2010.
  4. Yu L, Aoki C, Shimizu Y, Shimizu K, Hou W, Yagyu F, Wen X, Oshima M, Iwamoto A, Gao B, Liu W, Gao GF, Kitamura Y. Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication. J Virol Methods. 169:380-4, 2010.

2009

  1. Liu X, Sun L, Yu M, Wang Z, Xu C, Xue Q, Zhang K, Ye X, Kitamura Y, Liu W. Cyclophilin A interacts with influenza A virus M1 protein and impairs the early stage of the viral replication. Cellular Microbiology. 11:730-741, 2009.
  2. Sun L, Zhang G, Shu Y, Chen X, Zhu Y, Yang L, Ma G, Kitamura Y, Liu W. Genetic correlation between H3N2 human and swine influenza viruses. J Clin Virol. 44:141-144, 2009.

2008

  1. Hou W, Aoki C, Yu L, Wen X, Xue Y, Gao B, Liu W, Gao GF, Iwamoto A, Kitamura Y. A recombinant replication-competent hepatitis C virus expressing Azami-Green, a bright green-emitting fluorescent protein, suitable for visualization of infected cells. Biochem. Biophys. Res. Commun. 377:7-11, 2008.
  2. Hosoya N, Miura T, Kawana-Tachikawa A, Koibuchi T, Shioda T, Odawara T, Nakamura T, Kitamura Y, Kano M, Kato A, Hasegawa M, Nagai Y, Iwamoto A. Comparison between Sendai virus and adenovirus vectors to transduce HIV-1 genes into human dendritic cells. J Med. Virol. 80:373-82, 2008.
  3. Qin Z, Sun L, Ma B, Cui Z, Zhu Y, Kitamura Y, Liu W. F gene recombination between genotype II and VII Newcastle disease virus. Virus Res.131:299-303,2008.

2007

  1. Tian K, Yu X, Zhao T, Feng Y, Cao Z, Wang C, Hu Y, Chen X, Hu D, Tian X, Liu D, Zhang S, Deng X, Ding Y, Yang L, Zhang Y, Xiao H, Qiao M, Wang B, Hou L, Wang X, Yang X, Kang L, Sun M, Jin P, Wang S, Kitamura Y, Yan J, Gao GF. Emergence of fatal PRRSV variants: unparalleled outbreaks of atypical PRRS in China and molecular dissection of the unique hallmark. PLoS ONE. 13;2(6):e526, 2007.
  2. Wichukchinda N, Kitamura Y, Rojanawiwat A, Nakayama EE, Song H, Pathipvanich P, Auwanit W, Sawanpanyalert P, Iwamoto A, Shioda T, Ariyoshi K. The polymorphisms in DC-SIGNR affect susceptibility to HIV type 1 infection. AIDS Res Hum Retroviruses. 23:686-92, 2007.

学会発表

2024

  1. Identification of a broadly neutralizing antibody against the SARS-CoV-2 Spike S2 domain. Mizuki Yamamoto, Yoko Hirayama, Jun-ichiro Inoue, Yasushi Kawaguchi, Jin Gohda. 第71回日本ウイルス学会学術集会, ウインクあいち, 愛知県名古屋市, 2024/11/4-6, (Poster).
  2. Identification of a broadly neutralizing antibody against the SARS-CoV-2 Spike S2 domain. Mizuki Yamamoto, Yoko Hirayama, Jun-ichiro Inoue, Yasushi Kawaguchi, Jin Gohda, 第2回UTOPIAシンポジウム, クロス・ウェーブ府中, 東京都府中市, 2024/6/19-20, (Poster).
  3. Metalloproteinase-dependent and TMPRSS2-independnt cell surface entry pathway of SARS-CoV-2 requires the furin-cleavage site and the S2 domain of spike protein. Mizuki Yamamoto, Jin Gohda, Yasushi Kawaguchi, Jun-Ichiro Inoue. Proteolysis at the membrane-from signaling to disease, Kloster Seeon, Germany, 2024/5/13-16, (Poster).
  4. Research for SARS-CoV-2 inhibitors from subtropical bioresources in the Ryukyu islands. Takayuki Ogi, Mizuki Yamamoto, Idam Hermawan, Hiroto Yokaryo, Jun-ichiro Inoue. 日本薬学会第144年会, パシフィコ横浜, 神奈川県横浜市, 2024/3/28-31, (Poster).

2023

  1. Comparison of rat anti-SARS-CoV-2 spike neutralizing antibody with existing antibody drugs by deep mutational analysis. Mizuki Yamamoto, Jin Gohda, Keiko Tomita, Youko Hirayama, Yasushi Kawaguchi, Jun-ichiro Inoue. 第70回日本ウイルス学会学術集会, 仙台国際センター, 宮城県仙台市, 2023/9/26-28, (Oral).
  2. SARS-CoV-2の膜融合アッセイを利用した感染阻害剤の探索. 山本瑞生. 第17回ウイルス学キャンプin湯河原, ニューウェルシティ湯河原, 静岡県熱海市, 2023/6/26, (Poster).
  3. SARS-CoV-2のメタロプロテアーゼ依存的な感染機構の解析. Mizuki Yamamoto, Jin Gohda, Ayako Kobayashi, Keiko Tomita, Youko Hirayama, Naohiko Koshikawa, Motoharu Seiki, Kentaro Semba, Tetsu Akiyama, Yasushi Kawaguchi and Jun-ichiro Inoue. 第1回新型コロナウイルス研究集会, 渋谷キューズ, 東京都渋谷区, 2023/6/9, (Oral).

2022

  1. SARS-CoV-2 の細胞内侵入経路とその阻害剤の探索. 山本瑞生. 日本薬学会関東支部 第47 回学術講演会, 東京都港区, 2022/11/26, (Oral).
  2. メタロプロテアーゼに依存するSARS-CoV-2感染にはSpikeタンパク質のFurin切断モチーフとS2ドメインが重要である. 山本瑞生, 合田仁, 小林絢子, 冨田恵子, 平山榕子, 越川直彦, 清木元治, 仙波憲太郎, 秋山徹, 川口寧, 井上純一郎. 第69回日本ウイルス学会学術集会, 出島メッセ長崎, 長崎県長崎市, 2022/11/13-15, (Oral).

2021

  1. ウイルスエンベロープタンパク質依存性膜融合の定量化のための細胞融合アッセイの確立Establishment of a cell fusion assay for the quantification of viral envelope protein-dependent membrane fusion. 山本瑞生, 井上純一郎, 川口寧, 合田仁. 第94回日本生化学会大会, Web開催, 2021/11/5,(Oral).
  2. Cell-based membrane fusion assay for flavivirus envelope proteins. Mizuki Yamamoto, Jun-ichiro Inoue, Yasushi Kawaguchi, Jin Gohda, The 62nd Annual Meeting for the Japanese Society of Tropical Medicine, Online, 2021/11/5,(Oral).
  3. 新型コロナウイルスのエンベロープタンパク質を用いた細胞融合アッセイの確立 Cell-based high throughput membrane fusion assay for SARS-CoV-2. 山本瑞生, 井上純一郎, 川口寧, 合田仁. 2021年度若手支援技術講習会, Web開催, 2021/9/6 (Oral).
  4. ウイルスエンベロープタンパク質依存性膜融合の定量化のための細胞融合アッセイの確立. 山本瑞生. 第21回Pharmaco-Hematologyシンポジウム, Web開催, 2021/5/22 (Oral).
  5. 新型コロナウイルス感染症治療薬シーズとしてのナファモスタットの同定. 山本瑞生. 第3回 Translational and Regulatory Sciences Symposium, Web開催, 2021/1/18, (Oral).

2020

  1. SARS-CoV-2 S依存的な細胞融合アッセイによる抗血液凝固剤ナファモスタットの抗ウイルス感染作用の発見　The anticoagulant Nafamostat potently inhibits SARS-CoV-2 S protein-mediated fusion in a cell fusion assay system and viral infection in vitro in a cell-type-dependent manner. Mizuki Yamamoto, Jun-ichiro Inoue, Yasushi Kawaguchi, Jin Gohda. 第43回日本分子生物学会年会, 2020/12/3, (Poster).

2018

  1. Chemical library screening for latency reverting agents to eradicate HIV-1.　Takaomi Ishida，Jin Gohda，Kazuo Suzuki，Kai Liu，Xialin Xie，Hiroaki Takeuchi，Jun-ichiro Inoue，Yasushi Kawaguchi. 第66回日本ウイルス学会学術集会, 京都市京都テルサ, 京都府京都市, 2018/10/28-30, (Oral).
  2. piCode Disk法を応用した高感度PCR法によるHIVウイルスリザーバー定量法の確立.　鈴木一雄, 石田尚臣. 第32回日本エイズ学会学術集会,大阪国際会議場, 大阪府, 2018/12/2-4, (Oral).
  3. HIV潜伏感染を制御する宿主因子の同定および解析. 武内寛明, 合田仁, 石田尚臣, 佐藤賢文, 岩瀬早織, 山岡昇司. 第32回日本エイズ学会学術集会,大阪国際会議場, 大阪府, 2018/12/2-4, (Oral).
  4. HIV感染に必要な細胞因子スクリーニングのためのジフテリア毒素とGFPのディアルスプリットタンパク質の構築. 合田仁, 武内寛明, 石田尚臣. 第32回日本エイズ学会学術集会, 大阪国際会議場, 大阪府, 2018/12/2-4, (Oral).
  5. HIV-1潜伏感染プロウイルスの再活性化を誘導する低分子化合物の探索. 合田仁, 鈴木一雄, 井上純一郎, 川口寧, 石田尚臣. 第32回日本エイズ学会学術集会, 大阪国際会議場, 大阪府, 2018/12/2-4, (Poster).

2017

  1. HIV潜伏感染プロウイルスの再活性化を誘導する低分子化合物の探索. 合田仁, 鈴木　一雄, 井上純一郎, 川口寧、石田尚臣. 第３１回日本エイズ学会学術集会, 東京都中野区, 2017/11/24, (Poster).

2016

  1. Establishment of model cell lines for studying the transcriptional suppression of the HIV-1 genes, Liu K, Gohda J, Inoue JI, Kawaguchi Y, and Ishida T, The 15th Awaji International Forum on Infection and Immunology, Hyogo, Japan, 2016/9/6-9, (poster)

2015

  1. Reevaluation of coreceptor usage for the HIV-1 CRF01_AE in China Lijun Gu, Yang Han, Feifei Yang, Ting Zhu, Xiaojing Song, Jing Xie, Jin Gohda, Jun-ichiro Inoue, Yasushi Kawaguchi, Taisheng Li , and Takaomi Ishida.The 63rd Annual Meeting of the Japanese Society for Virology, Fukuoka, Japan. November, 22-24, 2015.
  2. HIV-1 replicates in human osteoclasts and enhances their differentiation in vitro.Jin Gohda.The 33rd Annual Meeting of the Japanese Society for Bone and Mineral Research, Tokyo, Japan. July, 23-25, 2015.

2014

  1. Takaomi Ishida.
    HIV/AIDS research in China (Institute of Microbiology).
    Asian-African Research Forum on Emerging and Reemerging Infections 2014
    Working group meeting on specific diseases (HIV/Hepatitis), Sendai, Japan. January 20-22, 2014.
  2. Jin Gohda, Yijing Ma, Lijun Gu, Feifei Yang, Yang Li, Jun-ichiro Inoue, George Fu Gao, Bin Gao, Aikichi Iwamoto, Takaomi Ishida.
    Human osteoclasts as a new possible target for HIV-1.
    Asian-African Research Forum on Emerging and Reemerging Infections 2014
    Working group meeting on specific diseases (HIV/Hepatitis), Sendai, Japan. January 20-22, 2014.
  3. Lijun Gu, Yang Han, Ying Huang, Feifei Yang, Shuo Guan, Ting Zhu, Jin Gohda, Noriaki Hosoya, Jing Xie, Aikichi Iwamoto, Taisheng Li and Takaomi Ishida.
    Emergence of Lamivudine-resistant HBV during HAART including Lamivudine for patients co-infected with HIV and HBV in China.
    Asian-African Research Forum on Emerging and Reemerging Infections 2014
    Working group meeting on specific diseases (HIV/Hepatitis), Sendai, Japan. January 20-22, 2014.
  4. Shuo Guan, Lijun Gu, Yang Han, Ting Zhu, Feifei Yang, Ying Hung, Ying Cao, Qu Cui, Jin Gohda, Wenjun Liu, George Gao Fu, Aikichi Iwamoto, Taisheng Li and Takaomi Ishida.
    Human immunodeficiency virus type-1 (HIV-1) subtype and coreceptor-usage in treatment-naive patients in a Chinese cohort study.
    Asian-African Research Forum on Emerging and Reemerging Infections 2014
    Oral Session (S4) HIV/Hepatitis, Sendai, Japan. January 20-22, 2014.

2013

  1. Guan S, Gu L, Han Y, Zhu T, Yang F, Hung Y, Cao Y, Cui Q, Gohda J, Gao GF, Iwamoto A, Li T and Ishida T.
    Human immunodeficiency virus type-1 (HIV-1) subtype and coreceptor-usage in treatment-naive patients in a Chinese cohort study.
    The 9th China-Japan Joint Laboratory Workshop: Pathogenesis, Gene Regulation and Signal Transduction. November 1, 2013.
  2. Gu L, Han Y, Zhu T, Guan S, Yang F, Hung Y, Cao Y, Cui Q, Gohda J, Iwamoto A, Li T and Ishida T.
    Human immunodeficiency virus type-1 (HIV-1) subtype and coreceptor-usage in treatment-naive patients in a Chinese cohort study.
    中華医学会第六回全国エイズ・ウイルス性C型肝炎・全国熱帯病学術会議, ChongQing, China. October 18-19, 2013.
  3. Gu L, Han Y, Hung Y, Hosoya N, Zhu T, Gohda J, Xie J, Iwamoto A, Li T and Ishida T.
    Emergence of Lamivudine-resistant HBV during HAART including Lamivudine for patients co-infected with HIV and HBV in China.
    The 12th Awaji International Forum on Infection and Immunology, Awaji, Japan. September 10 -13, 2013.
  4. Gohda j, Ma Y, Gu L, Inoue J-i, Gao GF, Gao B, Iwamoto A, Ishida T.
    Human osteoclasts as a possible target for HIV-1 The 12th Awaji International Forum on Infection and Immunology, Awaji, Japan. September 10 -13, 2013.
  5. Gu L, Han Y, Hung Y, Hosoya N, Zhu T, Gohda J, Cui Q, Iwamoto A, Li T and Ishida T.
    Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay.
    7th IAS Conference on HIV Pathogenesis, Treatment and Prevention, Kuala Lumpur, Malaysia. June 3 - July 3, 2013.
  6. Gohda j, Ma Y, Gu L, Inoue JI, Gao GF, Gao B, Iwamoto A, Ishida T.
    Human osteoclasts as a new target for HIV-1.
    Keystone symposia. Immune activation in HIV infection: Basic machanisms and clinical implications. Colorado, USA. April 3-8, 2013.
  7. Li Y, Han Y, Xie J, Gu L, Li L, Li W, Wang H, Ishida T, Iwamoto A, Li T.
    CRF01_AE subtype is associated with faster disease progression in Chinese HIV-1 sexually infected patients.
    20th Conference on retroviruses and opportunistic infections 2013, Atlanta, USA. March 3-6, 2013.
  8. Gu L, Han Y, Zhu T, Yang F, Guan S, Hung Y, Cao Y, Cui Q, Gohda J, Iwamoto A, Li T, Ishida T.
    Characterization of human immunodeficiency virus type-1 (HIV-1) co-receptor tropism in treatment-naive patients in a Chinese cohort study.
    Asian African Research Forum 2013, Tokyo, Japan. January 23-24, 2013.
  9. Gohda J, Ma Y, Gu L, Yang F, Li Y, Inoue JI, Gao GF, Gao B, Iwamoto A, Ishida T.
    Human osteoclasts as a new target for HIV-1
    Asian African Research Forum 2013. Tokyo, Japan, January 23-24, 2013.

2012

  1. Gu L, Hosoya N, Tachikawa-Kawana A, Gohda J, Wang Y, Ma Y, Han Y, Li T, Gao GF, Iwamoto A, Ishida T.
    Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay
    XIX International AIDS Conference. Washington D.C., USA, July 22-27, 2012.
  2. Ishida T, Suzuki K, Yamagishi M, Watanabe T.
    HIV-1 gene expression repressed by the epigenetic regulation.
    Cold Spring Harbor Laboratory, The 2012 meeting on Retroviruses. NY, USA, May, 2012.
  3. Gu L, Hosoya N, Tachikawa-Kawana A, Gohda J, Wang Y, Ma Y, Han Y, Li T, Gao GF, Iwamoto A, Ishida T
    Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay.
    1st Asian Conference on Hepatitis B & C, HIV and Influenza. Beijing, China, May, 2012.
  4. Ishida T, Suzuki K, Yamagishi M, Miyake A, Cooper DA, Kelleher AD, Watanabe T.
    The Epigenetic Regulation of HIV-1 Virus Gene Expression.
    Keystone Symposia, Frontiers HIV Pathogenesis, Therapy and Eradication. Vancouver, Canada, March, 2012.
  5. Gu L, Hosoya N, Tachikawa-Kawana A, Gohda J, Wang Y, Ma Y, Han Y, Li T, Gao GF, Iwamoto A, Ishida T.
    Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay.
    Asia-Africa Research Forum on Emerging and Reemerging Infections 2012, Kobe, Japan. Jan, 2012.

2011

  1. Matsuda A., Yamagishi M., Kobayashi M., Hara T., Ishida T. & Watanabe T.
    The molecular mechanisms for repression of HIV-1 gene transcription by the Polycomb Groups in latent infected cells.
    第２５回日本エイズ学会年会. 東京. ２０１１年. １１月.
  2. Gu L, Hosoya N, Tachikawa-Kawana A,Nakamura H, Koga M, Matsushita M, Lu B, Miura T, Iwamoto A.
    HIV-1サブタイプ未同定の検体を用いた配列特異的オリゴプローブによる薬剤耐性変異の検出
    第２５回日本エイズ学会年会. 東京. ２０１１年.１１月.
  3. Gu L, Hosoya N, Tachikawa-Kawana A, Gohda J, Wang Y, Ma Y, Han Y, Li T, Gao GF, Iwamoto A, Ishida T.
    Rapid high throughput screening of drug resistance in HIV-HBV co-infected patients by PCR-SSOP Luminex assay.
    The 8th China-Japan Laboratory Workshop: Pathogenesis, Gene Regulation and Signal Transduction. Beijing, China. Nov, 2011.

2010

  1. Gu L, Kawana-Tachikawa A, Shiino T, Hosoya N, Nunoya J-I, Koibuchi T, Fujii T, Miura T, Matsushita M, Sugiura W, Aikichi Iwamoto.
    Development of a PCR-SSOP-Luminex Assay for HIV-1 Drug Resistance.
    United States-Japan Cooperative Medical Science Program 24th Joint Meeting of the AIDS Panels HIV resistance impact in Asia. Singapore, Singapore. Dec, 2010.
  2. Gu L, Kawana-Tachikawa A, Shiino T, Hosoya N, Nunoya J-I, Koibuchi T, Fujii T, Miura T, Matsushita M, Sugiura W, Aikichi Iwamoto.
    配列特異的オリゴプローブを用いたHIV-1薬剤耐性変異検出法の開発
    第24回日本エイズ学会年会. 東京. ２０１０年.１１月.
  3. Gohda J, Konno H, Inoue J-I.
    Role of TRAF6 in innate immune responses.
    Asia-African Research Forum on Emerging and Reemerging Infections 2010. Hanoi, Vietnam, Nov, 2010.
  4. Yu L. Aoki C, Yagyu F, Wen X, Iwamoto A, Kitamura Y.
    Development of a simple system for screening anti-hepatitis C virus drugs utilizing mutants capable of vigorous replication.
    Asia-African Research Forum on Emerging and Reemerging Infections 2010. Hanoi, Vietnam, Nov, 2010.
  5. Shi G. Yagyu F, Shimizu Y, Shimizu K, Oshima M, Iwamoto I, Gao B, Liu FW, Gao GF, Kitamura Y.
    A Single-cell-based System for Assaying Activity of the Internal Ribosome Entry Site of Hepatitis C Virus Utilizing Two Fluorescent Proteins,
    Asia-African Research Forum on Emerging and Reemerging Infections 2010. Hanoi, Vietnam, Nov, 2010.
  6. Ishida T, Suzuki K, Yamagishi M, Cooper DA, Kelleher AD, Semba K, Yamamoto T, Iwamoto A. Watanabe T.
    The Epgenetic Regulation of HIV-1 virus Gene Expression.
    The 7th Japan-China joint laboratory workshop pathogenesis, gene regulation, and signal transduction. Beijing, China, Oct, 2010.
  7. Gu L, Hosoya N, Kawana-Tachikawa A, Shiino T, Koibuchi T, Fujii T, Miura T, Matsushita M, Sugiura W, Iwamoto A.
    Development of a PCR-SSOP-Luminex Assay for HIV-1 Drug Resistance.
    The 7th Japan-China joint laboratory workshop pathogenesis, gene regulation, and signal transduction. Beijing, China, Oct, 2010.
  8. Yu L, Aoki C, Yagyu F, Wen X, Iwamoto A, Kitamura Y.
    Variants of hepatitis C virus JFH-1 strain adapted to Huh7 cells.
    The 7th China-Japan Joint Laboratory Workshop -Pathogenesis, Gene Regulation, and Signal Transduction. Beijin, China, Oct, 2010.
  9. Shi G, Yagyu F, Yu L, Shimizu Y, Shimizu K, Oshima M, Iwamoto I, Gao B, Liu FW, Gao GF, Kitamura Y.
    A bicistronic reporter system evaluating activity of the internal ribosome entry site of hepatitis C virus.
    The 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokohama, Japan. Sep, 2010.
  10. Yu L, Aoki C, Shimizu Y, Shimizu K, Yagyu F, Hou W, Oshima M, Iwamoto I, Gao B, Liu FW, Gao GF, Kitamura Y.
    Variants of Hepatitis C virus JFH1 strain which adapted to Huh7 cells,
    The 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokohama, Japan. Sep, 2010.
  11. Yagyu F, Aoki C, Yu L, Iwamoto I, Kitamura Y.
    Differential measurement of the number of plus- and minus- RNA molecules of hepatitis C virus in infected cells.
    The 17th International Meeting on Hepatitis C Virus and Related Viruses, Yokohama, Japan. Sep, 2010.
  12. Gu L, Kawana-Tachikawa A, Shiino T, Hosoya N, Nunoya J-I Koibuchi T, Fujii T, Miura T, Matsushita M, Sugiura W, Iwamoto A.
    Development of a PCR-SSOP-Luminex Assay for HIV-1 Drug Resistance.
    XVIII International AIDS conference. Vienna, Austria, Jul, 2010.

2008

  1. Yu L, Aoki C, Shimizu Y, Shimizu K, Hou W, Yagyu F, Masamichi O, Iwamoto A, Gao B, Liu FW, Gao GF, & Kitamura, Y.
    Variants of JFH1 strain of hepatitis C virus, which have adapted to cultured Huh7 cells.
    The 9th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms. Richmond, VA, USA, Nov, 2008.
  2. Kitamura Y.
    Interferon' s antiviral activity against hepatitis C virus infection. International Consortium of Anti-Virals,
    7th International Symposium - Challenging Pandemics: Science, Policy, Preparedness. Beijing, China. Nov, 2008.
  3. Aoki C, Yu L, Shimizu Y, Shimizu K, Oshima M, Liu FW, Gao GF, Iwamoto A, & Kitamura Y.
    Anti-HCV activity of interferon-inducible protein, IFI44/IFI44L.
    The 15th International Symposium on Hepatitis C Virus and Related Viruses. San Antonio, TX, USA. Oct, 2008.
  4. Yu L, Aoki C, Shimizu Y, Hou W, Yagyu F, Masamichi O, Iwamoto A, Gao B, Liu FW, Gao GF, Kitamura Y.
    Variants of JFH1 strain of hepatitis C virus, which have adapted to cultured Huh7 cells.
    The 8th Awaji International Forum on Infection and Immunity. Hyogo, Japan. Sep, 2008.
  5. Wei Y, Lu L, Wen X, Chen Z, Aoki C, Yagyu F, Iwamoto A, Gao B, Liu FW, Gao GF, Kitamura Y.
    Change of Viral RNA in a Chinese Patient Resistant to Interferon/Ribavirin Therapy for Hepatitis C Infection.
    The 8th Awaji International Forum on Infection and Immunity. Hyogo, Japan. Sep, 2008.
  6. Yu L, Aoki C, Shimizu Y, Hou W, Masamichi O, Iwamoto A, Liu FW, Gao GF, Kitamura Y.
    Adaptation of Hepatitis C Virus to Growth in Cell Culture.
    The 7th Japan-China International Conference of Virology. Tokyo, Japan. Jun, 2008.
  7. Aoki C, Yu L, Shimizu Y, Oshima M, Liu FW, Gao GF, Iwamoto A, Kitamura Y.
    Anti-hepatitis C virus activity of interferon-inducible protein, IFI44/IFI44L.
    The First China-Japan Joint Workshop on New-Generation vaccines for Infectious Diseases: Molecular Biology of Host-Pathogen Interaction. Beijing, China. May, 2008.
  8. Kitamura Y.
    Review of recent progress of lentiviral vectors.
    Meeting on Application of Gene Transfer Techniques for Neurosciences. Okazaki, Japan. Feb, 2008.
  9. Aoki C.
    Host gene response to HCV replication in vitro.
    Asian Research Forum 2008. Osaka, Japan. Jan, 2008.
  10. Kitamura Y.
    Research Progress in China-Japan Joint Laboratory of Institute of Microbiology, Chinese Academy of Sciences.
    Asian Research Forum 2008. Osaka, Japan. Jan, 2008.

2007

  1. Yu L, Hijikata M, Shimizu Y, Aoki C, Oshima M, Iwamoto A, Gao GF, Kitamura Y.
    New Family of Interferon Induced GTPases That Are Associates with Hepatitis C Virus Infection.
    The 8th Annual Symposium on Antiviral Drug Resistance: Targets and Mechanisms. Richmond，VA, USA. Nov, 2007.
  2. Kitamura, Y.
    Antibodies against integrase of human immunodeficiency virus type 1.
    International Symposium on Basic and Applied Immunobiology. Beijing, China. Oct, 2007.
  3. Aoki, C.
    Hepatitis C virus replication in cultured mammalian cells.
    International Symposium on Basic and Applied Immunobiology. Beijing, China. Oct, 2007.
  4. Yagyu, F.
    Epidemiological study of rotavirus and norovirus _among pediatric inpatients with acute gastroenteritis in Ho Chi Minh City, Vietnam.
    International Symposium on Basic and Applied Immunobiology. Beijing, China. Oct, 2007.
  5. Kitamura, Y.
    Interferon-induced protein 44 (IFI44) and its homolog.
    Symposium on Emerging Pathogens and Immunology. Beijing, China. Aug, 2007.
｜ホーム｜拠点の紹介｜微生物研究所｜ハルビン獣医研究所｜サイトマップ｜